FAQ: What is the Difference Between Biosimilars and Generics?

Thank you Boehringer Ingelheim for your support of this FAQ Video Module.

Join Tedra Gray, NP, as she explains how biosimilars and generics play a crucial role in modern medicine, especially in fields like gastroenterology, rheumatology, and dermatology. She explains the key differences between biosimilars and generic medications, helping both healthcare providers and patients make informed treatment decisions.

Generic medications are identical copies of brand-name drugs, containing the same active ingredients, dosage, and route of administration. These drugs are FDA-approved and become available once the patent for the original brand-name drug expires. On the other hand, biosimilars are highly similar but not identical to biologic drugs, which are derived from living organisms or cells. These medications are often used to treat complex diseases like inflammatory bowel disease (IBD), Crohn’s disease, and ulcerative colitis. While biosimilars must demonstrate no clinically meaningful differences in pharmacokinetics or pharmacodynamics, they are not exact replicas like generics due to the complexity of biologic drugs.

For gastroenterology patients and providers, understanding the differences between biosimilars and generics is essential when choosing effective treatment options. Whether managing chronic GI conditions or exploring cost-effective alternatives, recognizing these distinctions ensures better patient care. For more information on biosimilars, generics, and GI treatment strategies, visit the GHAPP website or GHAPP ACE 2.0 mobile app to stay informed and empowered in your healthcare journey!